Thursday, March 25, 2021 9:39:45 PM
Biotricity’s flagship Bioflux® product is a wearable medical device that enables physicians to accurately monitor and diagnose cardiac patients in real-time for effective treatment and pain management. While this technology alone targets a massive demographic, the Company’s full pipeline of remote cardiac monitoring and diagnostic solutions provides access to a multi-billion-dollar market hungry for digital innovation.
Speaking with SCV’s Stuart Smith, Dr. Al-Siddiq describes how Biotricity builds and delivers its technology to benefit patients, care providers and the broader healthcare industry, while building long-term value for the Company.
“What we’ve noticed primarily across healthcare, is that technology is owned by clinical players – players that are actually performing the diagnostic tests,” he says. “Our model is very different. We want to enable physicians, hospitals and organizations to do that work so we can stay focused on things of a technology company.”
Biotricity’s monitoring devices are built in-house and are reusable, which saves on costs and enables exponential revenue growth through a recurring technology fee and greater market reach.
“That’s where we have been really fortunate to have a cycle of growth over growth,” explains Dr. Al-Siddiq. “We have a sales force, and the idea is for us to continue to open up more clinics, more hospitals, and get our devices into more hands.”
Biotricity currently has a sales presence in 20 U.S. states. Near-term growth plans include launching more products from the Company’s pipeline and expanding its sales force to target a larger addressable market.
“The most successful medical device and pharma companies have a direct sales force in their key markets and then they have distribution elsewhere,” says Dr. Al-Siddiq. “We are following the exact same track.”
Dr. Al-Siddiq also highlights the experience of Biotricity’s staff and how it was able to leverage that expertise to stride through the challenges of the pandemic and meet demand for remote monitoring.
“Intelligent monitoring and the value of it became very, very clear because of the pandemic,” he says. “The awareness and the need for it increased. The ability to sell was of course limited, but despite that, we were able to grow … Once this pandemic is more under control, I think it’s going to actually crate a boost in our growth in the long term.”
As the Company ramps up its sales force, it is also focused on the release of a new product and uplisting to a national exchange for greater visibility. Of significance, says Dr. Al-Siddiq, is for investors to remember Biotricity’s application to the healthcare industry and how that affects revenues.
“We are a technology company, not a clinical company,” he tells Smith. “Our focus is providing technology to physicians and healthcare companies in a business model that is anchored in reimbursement and a reoccurring revenue model. That is something that creates and accelerated growth and gives us a very high value long term. Being a technology player with a reoccurring business model places us at the top of the food chain when it comes to how to value the company. And we’ve done that in a very specific and concerted way.”
The full interview can be heard at: https://www.smallcapvoice.com/interview-biotricity-btcy/.
Recent BTCY News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:02:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:18:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:55:34 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:15:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2023 08:57:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:38:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:26:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:14:24 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:05:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 09:29:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM